Analysis of PI3K pathway components in human cancers (original) (raw)

Cancer Treatment Reviews, 2004

The Phosphoinositide 3-Kinase Pathway in Human Cancer: Genetic Alterations and Therapeutic Implications

Current Genomics, 2007

Modulators of sensitivity and resistance to inhibition of PI3K identified in a pharmacogenomic screen of the NCI-60 human tumor cell line collection

Joffre Baker

PloS one, 2012

View PDFchevron_right

Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer

Julian Downward

2012

View PDFchevron_right

Targeting PI3K in Cancer: Any Good News?

Miriam Martini

Frontiers in Oncology, 2013

View PDFchevron_right

Mouse Models to Decipher the PI3K Signaling Network in Human Cancer

O. Renner

Current Molecular Medicine, 2009

View PDFchevron_right

PIK3CA C2 domain deletions hyperactivate phosphoinositide 3-kinase (PI3K), generate oncogene dependence and are exquisitely sensitive to PI3Kα inhibitors

carlos rubio arteaga

Clinical cancer research : an official journal of the American Association for Cancer Research, 2017

View PDFchevron_right

Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway

Pascal Furet

Future Medicinal Chemistry, 2009

View PDFchevron_right

PIK3CA mutations in human solid tumors: Role in sensitivity to various therapeutic approaches

Linda Steelman

Cell Cycle, 2009

View PDFchevron_right

Multiple Genetic Alterations within the PI3K Pathway Are Responsible for AKT Activation in Patients with Ovarian Carcinoma

Valter Agosti

PLoS ONE, 2013

View PDFchevron_right

Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness

Aggeliki Tserga

Virchows Archiv, 2016

View PDFchevron_right

The Structural Basis of PI3K Cancer Mutations: From Mechanism to Therapy

Ahmed Alhaj Ahmed

Cancer Research, 2014

View PDFchevron_right

Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities

Denis Jardim

Cancer

View PDFchevron_right

The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review

Federica Rascio

Cancers

View PDFchevron_right

Supplementary Figures 1 - 6 from Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models

Ling Huw

View PDFchevron_right

Targeting the PI3K/AKT/mTOR/NFkB Axis in Ovarian Cancer

Neveen Said

Journal of Cellular Immunology, 2020

View PDFchevron_right

Elevated PI3K signaling drives multiple breast cancer subtypes

Sean Egan

Oncotarget, 2011

View PDFchevron_right

A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations

Raju Kucherlapati

Cancer cell, 2017

View PDFchevron_right

Using Tandem Mass Spectrometry in Targeted Mode to Identify Activators of Class IA PI3K in Cancer

A. Turke

Cancer Research, 2011

View PDFchevron_right

PIK3CA Cooperates with Other Phosphatidylinositol 3'-Kinase Pathway Mutations to Effect Oncogenic Transformation

David Stokoe

Cancer Research, 2008

View PDFchevron_right

Targeting PI3K/Akt/mTOR Signaling in Cancer

Alessandra Mosca

Frontiers in oncology, 2014

View PDFchevron_right

Reactivation of AKT signaling following treatment of cancer cells with PI3K inhibitors attenuates their antitumor effects

Catherine Pythoud

Biochemical and Biophysical Research Communications, 2013

View PDFchevron_right

Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models

Hartmut Koeppen

Clinical Cancer Research, 2012

View PDFchevron_right

Development of Phosphoinositide-3 Kinase Pathway Inhibitors for Advanced Cancer

Geoffrey Shapiro

Current Oncology Reports, 2010

View PDFchevron_right

Activation of PI3K Is Associated with Reduced Survival in Renal Cell Carcinoma

Stephan Kruck

Urologia Internationalis, 2008

View PDFchevron_right

Data from Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models

Ling Huw

View PDFchevron_right

Inhibiting PI3K as a therapeutic strategy against cancer

Luis Paz-ares, Amancio Carnero

Clinical and Translational Oncology, 2009

View PDFchevron_right

AKT-independent PI3-K signaling in cancer – emerging role for SGK3

Richard Pearson

Cancer Management and Research, 2013

View PDFchevron_right

Targeting PI3KC2β Impairs Proliferation and Survival in Acute Leukemia, Brain Tumours and Neuroendocrine Tumours

Alexandre Arcaro

View PDFchevron_right

Molecular changes in the phosphatidylinositide 3-kinase (PI3K) pathway are common in gastric cancer

Thang Tran Viet

Journal of Surgical Oncology, 2013

View PDFchevron_right

The Essential Role of Phosphoinositide 3-Kinases (PI3Ks) in Regulating Pro-Inflammatory Responses and the Progression of Cancer

Pablo Iribarren

2000

View PDFchevron_right

Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy.

Dawid G Nowak

View PDFchevron_right

3-Phosphoinositide–Dependent Kinase 1 Controls Breast Tumor Growth in a Kinase-Dependent but Akt-Independent Manner

Giorgio Seano, Paolo Armando Gagliardi, Francesca Orso, Federico Bussolino

2012

View PDFchevron_right

Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancer

Basma Bilal

BMC cancer, 2018

View PDFchevron_right

AKT-independent PI3-K signaling in cancer – emerging role for SGK3

Ross Hannan

Cancer Management and Research, 2013

View PDFchevron_right

Analysis of PI3K pathway components in human cancers (original) (raw)

Related papers